Authors
Latest:
Dr McKenzie on Updates to ASCO Treatment Guidelines in Metastatic Breast CancerAndrew McKenzie, PhD, discusses the updates to the ASCO clinical practice guidelines for biomarker testing in patients with metastatic breast cancer.
Latest:
Dr Vahdat on the Role of Copper Depletion in Reducing Metastatic Disease Risk in TNBCLinda Vahdat, MD, MBA, discusses the role of copper depletion in reducing the risk of metastatic disease development in triple-negative breast cancer.
Latest:
Novel HER2-Targeted Therapies for NSCLCClosing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.
Latest:
Dr Chao on the Correlation Between Broad-Spectrum Antibiotics and Early-Onset CRCChun Chao, PhD, MS, discusses the association between the use of broad-spectrum antibiotics and the risk of developing early-onset colorectal cancer.
Latest:
Dr. Politi on Drug-Tolerant Persister Cells in Cancer CareKaterina Politi, PhD, discusses drug-tolerant persister cells in patients with cancer.
Latest:
Key Takeaways and Clinical Pearls in the Treatment of R/R ALLThe key opinion leaders provide concluding insights and essential recommendations regarding the management of relapsed/refractory acute lymphoblastic leukemia.
Latest:
Dr Ornstein on the Use of IO/TKI Doublets in Non-ccRCCMoshe Ornstein, MD, MA, discusses the use of first-line IO/TKI doublet regimens in patients with non–clear cell renal cell carcinoma.
Latest:
Dr. Ghidini on the Effects of Body Weight Loss in Gastric/GEJ CancerMichele Ghidini, MD, PhD, discusses the effects of body weight loss in gastric/gastroesophageal junction cancer.
Latest:
Dr. Niemann on Notable Findings from the GLOW Trial in CLLCarsten Niemann, MD, PhD, discusses notable data on patient survival outcomes, as well as the impact of minimal residual disease in the peripheral blood from the phase 3 GLOW trial in patients with chronic lymphocytic leukemia.
Latest:
Disparities in Multiple Myeloma Care: The Path Toward Health EquityExpert panelists share their closing thoughts on the path to improve health equity in multiple myeloma management for racial and ethnic minority groups.
Latest:
Dr. Treon on the Evolution of BTK Inhibitors in Waldenström MacroglobulinemiaSteven P. Treon, MD, PhD, discusses the role of BTK inhibitors in Waldenström macroglobulinemia.
Latest:
Looking Ahead: Expert Future Perspectives in HR+ Breast CancerIn their concluding remarks, Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, summarize their key insights and perspectives on the management of HR+ breast cancer.
Latest:
Dr Hutson on the Final OS Analysis of the CLEAR Study in Advanced RCCThomas Hutson, DO, discusses the final prespecified overall survival analysis of the phase 3 CLEAR study in patients with advanced renal cell carcinoma.
Latest:
Dr Ip on the Impact of BCMA Alternative Splicing in Lymphoma and Multiple MyelomaAndrew Ip, MD, discusses alternative splicing of the TNFRSF17 gene, which encodes BCMA, in patients with lymphoma or multiple myeloma.
Latest:
Dr. Tkaczuk on the Utilization of Trastuzumab Deruxtecan in HER2+ Breast CancerKatherine Tkaczuk, MD, discusses the utilization of trastuzumab deruxtecan in HER2-positive breast cancer.
Latest:
Unmet Needs and Looking Ahead in Essential ThrombocythemiaUnmet needs and current areas that are being studied in in essential thrombocythemia.
Latest:
Dr Islam on Treatment of Patients With Hodgkin Lymphoma With or Without HIVJessica Yasmine Islam, PhD, MPH, discusses the treatment of patients with Hodgkin’s lymphoma who do or do not have HIV.
Latest:
Dr. Pavel on the PFS With Lanreotide Autogel in the CLARINET FORTE TrialMarianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.
Latest:
Dr Classe on Lymphadenectomy Omission in Advanced Epithelial Ovarian CancerJean-Marc Classe, MD, PhD, discusses lymphadenectomy omission following cytoreductive surgery after chemotherapy in advanced epithelial ovarian cancer.
Latest:
Not All Stage I and II Endometrial Cancers Are AlikeA recent retrospective study found that patients with endometrial cancer in International FICO stage I high- intermediate risk subgroups with fewer than 2 risk factors had a greater than 95% cause-specific survival at 3-year follow-up, and subgroups with 2 or more risk factors had poorer outcomes.
Latest:
Dr. Ross on Toxicity Concerns With Combination Therapies in EGFR+ NSCLCHelen J. Ross, MD, discusses toxicity concerns with combinations therapies in EGFR-mutant non–small cell lung cancer.
Latest:
Dr Hernandez-Ilizaliturri on Selecting Between CAR T-Cell Therapies for FLFrancisco Hernandez-Ilizaliturri, MD, discusses factors that inform the selection of CAR T-cell therapies for patients with follicular lymphoma.
Latest:
Cancer Care in 2024: Striving to Overcome the ChallengesManmeet S. Ahluwalia, MD, MBA, FASCO, discusses ongoing efforts to overcome challenges in cancer care in 2024.
Latest:
Dr. Usmani on the Rapidly Evolving Landscape in Multiple MyelomaSaad Z. Usmani, MD, MBA, FACP, discusses the rapidly evolving treatment landscape in multiple myeloma.
Latest:
Dr Lee on the Rationale for Investigating Linvoseltamab in R/R Multiple MyelomaHans Lee, MD, discusses the rationale for the phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.
Latest:
New Framework for Genetic Testing in Prostate Cancer Takes ShapeIn recent years, great progress has been made in understanding the genetics of metastatic prostate cancer which has translated into the development of new precision therapies.
Latest:
New Breast Center at UI Health Care Aims to Ease the Cancer Journey for PatientsThe new breast center at UI Holden Comprehensive Cancer Center aims to make the cancer journey easier and less stressful for patients by providing access to the state's most advanced cancer services in 1 convenient location.
Latest:
Dr Cobain on the Importance of Molecular Testing in Metastatic Breast CancerErin Frances Cobain, MD, discusses the importance of molecular testing in patients with metastatic breast cancer.
Latest:
Dr Foldi on T-DXd and Sacituzumab Govitecan in Metastatic Breast CancerJulia Foldi, MD, PhD, discusses the utility of of T-DXd and sacituzumab govitecan in the treatment of metastatic HER2-low and triple-negative breast cancer.
